Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models

The discovery of actionable targets is crucial for targeted therapies and is also a constituent part of the drug discovery process. The success of an intervention over a target depends critically on its contribution, within the complex network of gene interactions, to the cellular processes responsible for disease progression or therapeutic response. Here we present PathAct, a web server that predicts the effect that interventions over genes (inhibitions or activations that simulate knock-outs, drug treatments or over-expressions) can have over signal transmission within signaling pathways and, ultimately, over the cell functionalities triggered by them. PathAct implements an advanced graphical interface that provides a unique interactive working environment in which the suitability of potentially actionable genes, that could eventually become drug targets for personalized or individualized therapies, can be easily tested. The PathAct tool can be found at: http://pathact.babelomics.org.

[1]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[2]  Joaquín Dopazo,et al.  Understanding disease mechanisms with models of signaling pathway activities , 2014, BMC Systems Biology.

[3]  Francisco Salavert,et al.  Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity , 2015, Scientific Reports.

[4]  Susumu Goto,et al.  Data, information, knowledge and principle: back to metabolism in KEGG , 2013, Nucleic Acids Res..

[5]  Theresa Zhang,et al.  Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.

[6]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[7]  M. Warmuth,et al.  Targeted Cancer Therapies in the Twenty‐First Century: Lessons From Imatinib , 2010, Clinical pharmacology and therapeutics.

[8]  Rosa D. Hernansaiz-Ballesteros,et al.  Babelomics 5.0: functional interpretation for new generations of genomic data , 2015, Nucleic Acids Res..

[9]  Rosa D. Hernansaiz-Ballesteros,et al.  Assessing the impact of mutations found in next generation sequencing data over human signaling pathways , 2015, Nucleic Acids Res..

[10]  Francisco Salavert,et al.  Inferring the functional effect of gene expression changes in signaling pathways , 2013, Nucleic Acids Res..

[11]  Marta Bleda,et al.  CellBase, a comprehensive collection of RESTful web services for retrieving relevant biological information from heterogeneous sources , 2012, Nucleic Acids Res..

[12]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.

[13]  Walter Kolch,et al.  Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients , 2015, Science Signaling.

[14]  Nikhil Wagle,et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.